Stockscreener 앱 받기
12.88
6.62%
0.80
시간 외 거래:
12.88
전일 마감가:
$12.08
열려 있는:
$12.08
하루 거래량:
1.47M
Relative Volume:
1.54
시가총액:
$1.08B
수익:
$7.62M
순이익/손실:
$-271.60M
주가수익비율:
-3.6781
EPS:
-3.5018
순현금흐름:
$-271.54M
1주 성능:
+9.43%
1개월 성능:
+4.29%
6개월 성능:
-23.92%
1년 성능:
+44.72%
1일 변동 폭
$12.05
$13.08
1주일 범위
$11.58
$13.33
52주 변동 폭
$7.94
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
명칭
Eyepoint Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
12.88 | 1.01B | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Inc 주식(EYPT)의 최신 뉴스
New hires at EyePoint receive 39,700 stock options package - Stock Titan
(EYPT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
EyePoint Pharmaceuticals Stock (US30233B1098): Analyst views and valuation in focus - AD HOC NEWS
EyePoint Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
EYPT: Phase III retinal drug aims for six-month dosing, rapid vision gains, and commercial readiness - TradingView
EyePoint outlines mid-2026 topline data target for DURAVYU in wet AMD and DME as Phase III trials advance - MSN
COMMODORE CAPITAL LP Increases Stake in EyePoint Inc - GuruFocus
JonesTrading Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Earnings call transcript: Eyepoint Pharmaceuticals misses Q1 2026 EPS and revenue forecasts - Investing.com
(EYPT) Risk Channels and Responsive Allocation - Stock Traders Daily
EyePoint Pharmaceuticals eyes transformative 2026 as DURAVYU Phase 3 data nears - MSN
EYPT: DURAVYU nears pivotal phase III readouts, targeting reduced treatment burden and strong safety - TradingView
Commodore Capital (EYPT) discloses 4.25M-share, 5.1% stake in EyePoint - Stock Titan
EYPT News | EYEPOINT INC (NASDAQ:EYPT) - ChartMill
EyePoint (NASDAQ: EYPT) CFO exercises RSUs, uses shares to cover tax - Stock Titan
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears - Yahoo Finance
EYPT: DURAVYU's pivotal trial results are imminent, targeting six-month dosing and market differentiation - TradingView
EYPT: DURAVYU Phase III data expected in August, targeting six-month dosing and U.S. launch in 2025 - TradingView
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
(EYPT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
EyePoint Inc. (EYPT) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineAnnual Financial Report - The Legal Advocate
How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets - Yahoo Finance
EyePoint Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
Should I Buy EYPT (EyePoint Pharmaceuticals, Inc.) | AI Analysis, Technical & News Insights - Kavout
EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards | EYPT Stock News - Quiver Quantitative
EyePoint hands new hires 158,100 stock options at $12.35 - Stock Titan
Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness - Yahoo Finance
[SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - Sahm
EyePoint’s DURAVYU Receives Third Consecutive Positive DSMC Review for Wet AMD - The Clinical Trial Vanguard
EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review - Moomoo
EyePoint (EYPT) Receives Positive Review for Duravyu Trials - GuruFocus
EyePoint Pharmaceuticals stock (US30233B1098): Phase 3 trials clear third safety review - AD HOC NEWS
EyePoint Announces Third Positive DSMC Review for DURAVYU Phase 3 Wet AMD Trials, Topline Data Expected Mid-2026 - Minichart
EyePoint's late-stage eye drug trials to continue after safety panel review - TradingView
EyePoint’s wet AMD trial continues after safety review By Investing.com - Investing.com Australia
Eyepoint announces third consecutive positive DSMC recommendation for phase 3 wet AMD trials for Duravyu(TM), building confidence ahead of mid-2026 topline data - marketscreener.com
EyePoint Advances DURAVYU Phase 3 Wet AMD Program - TipRanks
EyePoint’s wet AMD trial continues after safety review - Investing.com India
EyePoint receives third positive DSMC review; Phase 3 topline data on track for mid-2026 - TradingView
Third positive DSMC review backs EyePoint (EYPT) Phase 3 DURAVYU wet AMD trials - Stock Titan
Eyepoint Inc Announces Third Consecutive Positive Dsmc Recommendation for Phase 3 Wet Amd Trials for Duravyu - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
EyePoint: DURAVYU's Durability Could Drive Significant Upside (NASDAQ:EYPT) - Seeking Alpha
Adage Capital files amendment: 3,300,000 shares in EyePoint (EYPT) disclosed - Stock Titan
TradingKey - TradingKey
Liquidity Mapping Around (EYPT) Price Events - Stock Traders Daily
EyePoint Pharmaceuticals stock (US30233B1098): Trading at discount to fair value estimates - AD HOC NEWS
Mizuho Securities Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
Eyepoint Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Eyepoint Inc 주식 (EYPT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ribeiro Ramiro | Chief Medical Officer |
Apr 17 '26 |
Option Exercise |
8.26 |
2,437 |
20,130 |
2,437 |
| Ribeiro Ramiro | Chief Medical Officer |
Apr 17 '26 |
Sale |
15.00 |
2,437 |
36,555 |
0 |
1.27%
1.43%
자본화:
|
볼륨(24시간):